First Time Loading...

Sight Sciences Inc
NASDAQ:SGHT

Watchlist Manager
Sight Sciences Inc Logo
Sight Sciences Inc
NASDAQ:SGHT
Watchlist
Price: 5.14 USD -8.54% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

SGHT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. [ Read More ]

The intrinsic value of one SGHT stock under the Base Case scenario is 7.73 USD. Compared to the current market price of 5.14 USD, Sight Sciences Inc is Undervalued by 33%.

Key Points:
SGHT Intrinsic Value
Base Case
7.73 USD
Undervaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sight Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SGHT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Sight Sciences Inc

Provide an overview of the primary business activities
of Sight Sciences Inc.

What unique competitive advantages
does Sight Sciences Inc hold over its rivals?

What risks and challenges
does Sight Sciences Inc face in the near future?

Has there been any significant insider trading activity
in Sight Sciences Inc recently?

Summarize the latest earnings call
of Sight Sciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sight Sciences Inc.

Provide P/S
for Sight Sciences Inc.

Provide P/E
for Sight Sciences Inc.

Provide P/OCF
for Sight Sciences Inc.

Provide P/FCFE
for Sight Sciences Inc.

Provide P/B
for Sight Sciences Inc.

Provide EV/S
for Sight Sciences Inc.

Provide EV/GP
for Sight Sciences Inc.

Provide EV/EBITDA
for Sight Sciences Inc.

Provide EV/EBIT
for Sight Sciences Inc.

Provide EV/OCF
for Sight Sciences Inc.

Provide EV/FCFF
for Sight Sciences Inc.

Provide EV/IC
for Sight Sciences Inc.

Show me price targets
for Sight Sciences Inc made by professional analysts.

What are the Revenue projections
for Sight Sciences Inc?

How accurate were the past Revenue estimates
for Sight Sciences Inc?

What are the Net Income projections
for Sight Sciences Inc?

How accurate were the past Net Income estimates
for Sight Sciences Inc?

What are the EPS projections
for Sight Sciences Inc?

How accurate were the past EPS estimates
for Sight Sciences Inc?

What are the EBIT projections
for Sight Sciences Inc?

How accurate were the past EBIT estimates
for Sight Sciences Inc?

Compare the revenue forecasts
for Sight Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sight Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sight Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sight Sciences Inc compared to its peers.

Compare the P/E ratios
of Sight Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sight Sciences Inc with its peers.

Analyze the financial leverage
of Sight Sciences Inc compared to its main competitors.

Show all profitability ratios
for Sight Sciences Inc.

Provide ROE
for Sight Sciences Inc.

Provide ROA
for Sight Sciences Inc.

Provide ROIC
for Sight Sciences Inc.

Provide ROCE
for Sight Sciences Inc.

Provide Gross Margin
for Sight Sciences Inc.

Provide Operating Margin
for Sight Sciences Inc.

Provide Net Margin
for Sight Sciences Inc.

Provide FCF Margin
for Sight Sciences Inc.

Show all solvency ratios
for Sight Sciences Inc.

Provide D/E Ratio
for Sight Sciences Inc.

Provide D/A Ratio
for Sight Sciences Inc.

Provide Interest Coverage Ratio
for Sight Sciences Inc.

Provide Altman Z-Score Ratio
for Sight Sciences Inc.

Provide Quick Ratio
for Sight Sciences Inc.

Provide Current Ratio
for Sight Sciences Inc.

Provide Cash Ratio
for Sight Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Sight Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Sight Sciences Inc?

What is the current Free Cash Flow
of Sight Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sight Sciences Inc.

Financials

Balance Sheet Decomposition
Sight Sciences Inc

Current Assets 162.9m
Cash & Short-Term Investments 138.1m
Receivables 14.3m
Other Current Assets 10.5m
Non-Current Assets 3.8m
PP&E 3.1m
Other Non-Current Assets 682k
Current Liabilities 12.3m
Accounts Payable 1.7m
Accrued Liabilities 8.3m
Other Current Liabilities 2.2m
Non-Current Liabilities 34.2m
Long-Term Debt 31.7m
Other Non-Current Liabilities 2.5m
Efficiency

Earnings Waterfall
Sight Sciences Inc

Revenue
81.1m USD
Cost of Revenue
-11.9m USD
Gross Profit
69.2m USD
Operating Expenses
-126.4m USD
Operating Income
-57.3m USD
Other Expenses
1.7m USD
Net Income
-55.5m USD

Free Cash Flow Analysis
Sight Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

SGHT Profitability Score
Profitability Due Diligence

Sight Sciences Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

32/100
Profitability
Score

Sight Sciences Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

SGHT Solvency Score
Solvency Due Diligence

Sight Sciences Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
54/100
Solvency
Score

Sight Sciences Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGHT Price Targets Summary
Sight Sciences Inc

Wall Street analysts forecast SGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SGHT is 5.74 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

Lowest
Price Target
5.05 USD
2% Downside
Average
Price Target
5.74 USD
12% Upside
Highest
Price Target
7.35 USD
43% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SGHT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SGHT Price
Sight Sciences Inc

1M 1M
+2%
6M 6M
+298%
1Y 1Y
-47%
3Y 3Y
-85%
5Y 5Y
-85%
10Y 10Y
-85%
Annual Price Range
5.14
52w Low
1.29
52w High
10.67
Price Metrics
Average Annual Return -38.87%
Standard Deviation of Annual Returns 10.89%
Max Drawdown -97%
Shares Statistics
Market Capitalization 252.5m USD
Shares Outstanding 49 553 400
Percentage of Shares Shorted 4.06%

SGHT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Sight Sciences Inc Logo
Sight Sciences Inc

Country

United States of America

Industry

Health Care

Market Cap

252.5m USD

Dividend Yield

0%

Description

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.

Contact

CALIFORNIA
Menlo Park
3000 Sand Hill Road, Building 3, Suite 105
+14158890550.0
https://www.sightsciences.com/

IPO

2021-07-15

Employees

212

Officers

Co-Founder, President, CEO & Director
Mr. Paul Badawi
Founder, CTO & Director
Dr. David Badawi M.D.
Chief Operating Officer
Mr. Sam Boong Park
CFO & Treasurer
Ms. Alison Perry Bauerlein
Chief Legal Officer
Mr. Jeremy B. Hayden
VP and Chief Ethics & Compliance Officer
Mr. Steve R. Tamayo Jr.
Show More
Chief Medical Officer
Dr. Reay H. Brown
Head of Corporate Strategy & Development
Tom Huang
Chief Commercial Officer
Mr. Matthew W. Link
Secretary
Mr. Stephen B. Thau J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGHT stock?

The intrinsic value of one SGHT stock under the Base Case scenario is 7.73 USD.

Is SGHT stock undervalued or overvalued?

Compared to the current market price of 5.14 USD, Sight Sciences Inc is Undervalued by 33%.